{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Liminatus Pharma, Inc.
Liminatus Pharma Stock Plummets to New 52-Week Low of $1.24
Liminatus Pharma, Inc. has reached a new 52-week low, reflecting its challenging performance compared to the S&P 500. With a market cap of USD 63 million, the company faces significant hurdles, including a negative price-to-book ratio and a troubling return on equity, highlighting the volatility in the biotechnology sector.
Liminatus Pharma Stock Plummets to New 52-Week Low of $1.58
Liminatus Pharma, Inc. has reached a new 52-week low of USD 1.58, contrasting sharply with its previous high of USD 33.66. The company, with a market cap of USD 63 million, faces significant financial challenges, including a negative return on equity and a unique debt-to-equity ratio.
Liminatus Pharma Stock Plummets to New 52-Week Low of $1.75
Liminatus Pharma, Inc. has reached a new 52-week low of USD 1.75, significantly down from its earlier high of USD 33.66. With a market capitalization of approximately USD 63 million, the company faces challenges, including a notably negative return on equity and a unique debt-to-equity ratio.
Liminatus Pharma Stock Plummets to New 52-Week Low of $1.81
Liminatus Pharma, Inc. has reached a new 52-week low of USD 1.81, reflecting its challenging performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 63 million, the company faces significant financial hurdles, including a negative return on equity and a low price-to-book ratio.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
